Skip to main content

Advertisement

Table 3 Effectiveness and mortality analyses for each treatment group as defined per bacteriologic documentation (visit 2)

From: Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study

  Group I Group II Group III Group IV Group V Overall
Effectiveness response rates       
Modified intention-to-treat population (n = 113) (n = 14) (n = 38) (n = 56) (n = 23) (n = 244)
   End of therapy (visit 3) (%) 81.4 78.6 68.4 75.0 56.5 75.4
   Final evaluation (visit 4) (%) 54.0 64.3 44.7 50.0 34.8 50.4
Patient-evaluable population (n = 100) (n = 11) (n = 36) (n = 48) (n = 18) (n = 213)
   Final evaluation (visit 4) (%) 61.0 81.8 47.2 58.3 44.4 57.7
Mortality rates       
Patient-evaluable population (n = 100) (n = 11) (n = 36) (n = 48) (n = 18) (n = 213)
   Overall mortality (%) 19.0 18.2 25.0 14.6 33.3 20.2
   Nosocomial pneumonia-attributable mortality (%) 15.0 9.1 8.3 8.3 33.3 13.6
Variables independently associated with overall mortality by logistic regression analysis Adjusted odds ratio 95% confidence interval P
Age (year of age) 1.019 1.001–1.038 0.033
Baseline APACHE II score (per point) 1.064 1.019–1.111 0.004
Treatment group (referred to Group V)      0.014
   Group I 0.341 0.118–0.859   
   Group II 0.116 0.020–0.691   
   Group III 0.341 0.108–1.080   
   Group IV 0.138 0.042–0.454   
Constant 0.151 0.038–0.607 -
  1. Forward stepwise logistic regression analysis (cut-off P value of 0.05) was used to determine the relationship between mortality and independent baseline variables previously identified in univariate analyses (P < 0.05), including: age, mechanical ventilation, Acute Physiology, Age, and Chronic Health Evaluation (APACHE) II score, treatment group, and adequacy of initial empiric therapy. Group I, patients with an unknown aetiology and unmodified therapy; Group II, patients with resistant organisms, who had unmodified therapy; Group III, patients with susceptible organisms, who had unmodified therapy; Group IV, patients who had susceptible organisms and whose therapy was modified accordingly; and Group V, patients who initially received inadequate antibiotic therapy, which was later modified on the basis of cultures.